Figure 4.

Combination treatment promotes gene expression associated with NASH resolution

(A) Hierarchical clustering of healthy human patients, patients with NAFLD/NASH, and experimental cohorts based on the standardized expression of prognostically significant orthologous genes involved in NASH progression.

(B) Classification of human-derived samples based on similarity to combination treatment gene signature identifies differential enrichment of parenchymal and nonparenchymal cell types between predicted classes. Boxplots show median and interquartile range, trailing lines represent 95% confidence interval. Outliers are represented by black circles. Difference between groups were assessed by Students’ t test and significance was accepted at p < 0.0056 to correct for Bonferroni multiple hypothesis testing.